Duncan Lyn McDivitt
Department of Pathology, Harvard Medical School, MGH Dermatopathology Unit WRN827, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Hematol Oncol Clin North Am. 2009 Jun;23(3):501-13, ix. doi: 10.1016/j.hoc.2009.03.013.
Forty years ago, a clinical and histological classification scheme and prognostic factors were described for cutaneous melanoma. This scheme included the subtypes superficial spreading, nodular and lentigo maligna, and prognostic factors including tumor thickness, ulceration, and mitotic activity. There have been some tweaks to the classification scheme, but these basic findings form the foundation for melanoma diagnosis and staging today. Currently, no molecular marker or target has proved reliably useful in the staging or treatment of melanoma. Measurement with a simple ruler serves as the basis for the staging of primary cutaneous melanoma, while the recognition of primary tumor mitotic activity and ulceration also remain significant factors. Recently, mutational analysis has revealed a correlation of activating mutations with the morphological descriptors from decades ago. Future classification schemes may have more power in predicting response to therapy by integrating specific genomic and intra-tumoral expression profiles with histologic findings.
四十年前,人们描述了一种皮肤黑色素瘤的临床和组织学分类方案及预后因素。该方案包括浅表扩散型、结节型和恶性雀斑样痣亚型,以及包括肿瘤厚度、溃疡和有丝分裂活性在内的预后因素。分类方案虽有一些微调,但这些基本发现构成了如今黑色素瘤诊断和分期的基础。目前,尚无分子标志物或靶点被证明在黑色素瘤的分期或治疗中可靠有用。用一把简单的尺子测量是原发性皮肤黑色素瘤分期的基础,而对原发性肿瘤有丝分裂活性和溃疡的识别也仍然是重要因素。最近,突变分析揭示了激活突变与几十年前的形态学描述符之间的相关性。未来的分类方案通过整合特定的基因组和肿瘤内表达谱与组织学发现,可能在预测治疗反应方面更具效力。